^
Association details:
Evidence:
Evidence Level:
Resistant: C4 – Case Studies
Title:

Upfront progression under pembrolizumab followed by a complete response after encorafenib and cetuximab treatment in BRAF V600E-mutated and microsatellite unstable metastatic colorectal cancer patient: A case report

Published date:
11/17/2021
Excerpt:
...the case of a patient with BRAF V600E, PIK3CA, and SMAD4 mutated and dMMR/MSI mCRC...The patient was progressive after a single cycle of pembrolizumab followed by a rapid complete response after only 2 months of treatment with encorafenib and cetuximab...
DOI:
10.1002/gcc.23012